Influence of Cardiopulmonary Rehabilitation on Cardiorespiratory Adaptation in Patients With Pulmonary Hypertension

N/ANot Yet RecruitingNCT07648524

Cairo University42 enrolled

Overview

This study aims to investigate the effect of cardiopulmonary rehabilitation on cardiorespiratory parameters and functional capacity in patients with pulmonary hypertension.

Pulmonary hypertension is a progressive disease associated with reduced exercise capacity, respiratory muscle weakness, and impaired quality of life. Exercise training and respiratory muscle training have been shown to improve physical performance and quality of life in patients with pulmonary hypertension. forty-two medically stable patients with Group III pulmonary hypertension due to lung diseases (obstructive and restrictive) will participate in this comparative experimental study. Participants will receive cardiopulmonary rehabilitation consisting of moderate-intensity interval aerobic training and inspiratory muscle training in addition to routine medical treatment. Outcome measures will include echocardiographic parameters, pulmonary function, six-minute walk distance, estimated VO2max, dyspnea severity, and quality of life. The study aims to evaluate the influence of cardiopulmonary rehabilitation on cardiorespiratory adaptation in patients with pulmonary hypertension.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Pulmonary Hypertension Due to Lung Disease (Disorder)

Interventions

cardiopulmonary rehabilitation in the form of moderate-intensity interval aerobic trainingBEHAVIORAL

Training will be conducted on a treadmill three times weekly for 12 weeks. Exercise intensity will progress from 30-40% to 60-70% of target heart rate. Each session will last 30 minutes and include warm-up and cool-down periods.

Inspiratory Muscle TrainingDEVICE

inspiratory muscle training will be performed using a Threshold Inspiratory Muscle Trainer (Philips Respironics). Training intensity will correspond to moderate-to-severe effort (3-5 on the Modified Borg Scale).

Medical treatmentOTHER

medication

Eligibility

Sex: ALLMin age: 45 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: \- a)Medically stable pulmonary hypertension patients who were under optimized medical therapy. b)Pulmonary artery pressure ≥ 25 mmHg confirmed by RT side heart catheterization. c)Forty two male patients with group 3 pulmonary hypertension (Chest cause) include Obstructive lung disease ( COPD and sleep apnea ) and restrictive lung disease (ILD). d)The patients' ages will range from 45 to 65 years old. e)BMI (25 - 34.9) kg/m2. f)World Health Organization (WHO) classification of functional classes II to III ( class II are patients with pulmonary hypertension who have a mild limitation of physical activity )(class III are patients with pulmonary hypertension who have a marked limitation of physical activity Exclusion Criteria: * g)Uncontrolled systemic HTN. h)Other types of pulmonary hypertension.. i)Smoker j)Any condition of kidney failure. k)Neurological or musculoskeletal conditions that interfere with gait l)Impaired vision and/or hearing. m)Patients who are unable to follow verbal instructions. n)acute exacerbation condition. o)unstable angina, serious cardiac dysrhythmias on resting ECG.

Locations (1)

Faculty of Physical Therapy ,Cairo University

Giza, Egypt

Outcomes

Primary Outcomes

6-minute walk distance

total distance walked in 6 minutes

Time frame: 12 weeks

Maximal Oxygen Consumption

Estimated VO2max

Time frame: 12weeks

spirometry

FEV1, FVC, FEV1/FVC, MVV

Time frame: 12weeks

Secondary Outcomes

Dyspnea Severity

Modified Borg Scale

Time frame: 12weeks

change Pulmonary Artery Pressure

pulmonary artery pressure estimated by ECHO

Time frame: 12weeks

change of total score of SF-12 Questionnaire) Quality of Life

more increase scores more increase quality of life

Time frame: 12weeks

Central Contacts

Rana Essam El Din Abd Elbar, Assistant lecturer

CONTACT

01013981766 rana.essam@acu.edu.eg

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.